Please login to the form below

Not currently logged in
Email:
Password:

NBE-Therapeutics

This page shows the latest NBE-Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Boehringer spends €1.18bn to acquire NBE-Therapeutics

NBE-Therapeutics, headquartered in Switzerland, is focused on antibody-drug conjugates (ADC) for the development of targeted cancer therapies. ... NBE-Therapeutics’ iADC platform adds exceptional tumour targeting capabilities to our oncology portfolio.

Latest news

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics